Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

3(60.0%)

Phase 1

1(20.0%)

Phase 4

1(20.0%)

5Total

Phase 2(3)

Phase 1(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT06078839Phase 4Not Yet Recruiting

Nafamostat Mesilate in the Treatment of Severe Infection-associated Coagulopathy

Role: collaborator

NCT05426811Phase 1Unknown

Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients

Role: collaborator

NCT04433403Unknown

Pathogenic Microorganisms in Adult Severe Pneumonia Patients

Role: collaborator

NCT04612673Phase 2Unknown

A Phase II Study of Anti-PD-1 Antibody, Sintilimab, as Second-line Therapy for Biomarker-selected Advanced or Metastatic NSCLC

Role: collaborator

NCT03116555Phase 2Unknown

Apatinib Plus Irinotecan as Second-line Treatment in AGC or EGJA

Role: collaborator

NCT03732001Phase 2Unknown

A Study of Anlotinib in Combination With Docetaxel Versus Docetaxel Alone in Participants With Advanced NSCLC

Role: collaborator

All 6 trials loaded